BECTON DICKINSON & CO
BDX
44 insider filings · Latest: Sep 28, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | May 27 5:41 PM | Michael FeldEVP, Chief Revenue Officer | Sale | 75 | $147.35 | $11.1K | 21,084(D) | View → |
| May 26, 2026 | May 26 8:47 PM | MICHAEL FELD | Proposed Sale | 75 | $147.63 | $11.1K | — | View → |
| Apr 27, 2026 | Apr 28 11:44 AM | Michael FeldEVP, Chief Revenue Officer | Sale | 74 | $151.94 | $11.2K | 21,159(D) | View → |
| Apr 27, 2026 | Apr 27 8:34 PM | MICHAEL FELD | Proposed Sale | 74 | $152.14 | $11.3K | — | View → |
| Mar 26, 2026 | Mar 27 5:49 PM | Michael FeldEVP, Chief Revenue Officer | Sale | 75 | $156.83 | $11.8K | 21,233(D) | View → |
| Mar 26, 2026 | Mar 26 8:24 PM | MICHAEL FELD | Proposed Sale | 75 | $158.27 | $11.9K | — | View → |
| Feb 26, 2026 | Feb 27 10:45 PM | Michael FeldEVP, Chief Revenue Officer | Sale | 75 | $181.84 | $13.6K | 21,308(D) | View → |
| Feb 26, 2026 | Feb 26 9:26 PM | MICHAEL FELD | Proposed Sale | 75 | $180.96 | $13.6K | — | View → |
| Feb 20, 2026 | Feb 20 9:24 PM | DAVID MICHEL SHAN | Proposed Sale | 5,422 | $184.14 | $998.4K | — | View → |
| Feb 20, 2026 | Feb 20 9:20 PM | CHRISTOPHER DELOREFICE | Proposed Sale | 11,305 | $183.91 | $2.1M | — | View → |
| Feb 18, 2026 | Feb 18 10:20 PM | Bertram L ScottDirector | Sale | 953 | $182.61 | $174.0K | 36,763(D) | View → |
| Feb 18, 2026 | Feb 18 9:10 PM | CHRISTOPHER DELOREFICE | Proposed Sale | 9,366 | $182.46 | $1.7M | — | View → |
| Feb 18, 2026 | Feb 18 9:07 PM | BERTRAM SCOTT | Proposed Sale | 953 | $182.61 | $174.0K | — | View → |
| Jan 26, 2026 | Jan 28 2:46 PM | Michael FeldEVP, CRO & Pres. Life Sciences | Sale | 75 | $202.73 | $15.2K | 16,431(D) | View → |
| Jan 26, 2026 | Jan 26 9:31 PM | MICHAEL FELD | Proposed Sale | 75 | $201.79 | $15.1K | — | View → |
| Jan 15, 2026 | Jan 16 8:43 PM | Michael David GarrisonEVP & Pres Med.Essntl&BioPharm | Sale | 1,610 | $207.46 | $334.0K | 12,095(D) | View → |
| Jan 15, 2026 | Jan 15 9:22 PM | MICHAEL GARRISON | Proposed Sale | 1,610 | $207.42 | $333.9K | — | View → |
| Dec 26, 2025 | Dec 29 12:48 PM | MICHAEL FELD | Proposed Sale | 74 | $196.12 | $14.5K | — | View → |
| Dec 17, 2025 | Dec 17 9:24 PM | MICHAEL GARRISON | Proposed Sale | 629 | $196.39 | $123.5K | — | View → |
| Dec 1, 2025 | Dec 1 9:18 PM | MICHAEL FELD | Proposed Sale | 75 | $194.02 | $14.6K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Aug 14 8:36 PM | Thomas E Polen JrDirector, Chairman, CEO and President | Option Exercise | 43,278 | — | 0(D) | View → |
| Aug 6, 2026 | Aug 6 8:47 PM | Robert Luther HuffinesDirector | Grant/Award | 189 | — | 595(D) | View → |
| Aug 6, 2026 | Aug 6 8:47 PM | Carrie L ByingtonDirector | Grant/Award | 94 | — | 3,810(D) | View → |
| Jun 1, 2026 | Jun 3 4:44 PM | Thomas E Polen JrDirector, Chairman, CEO and President | Option Exercise | 20,209 | — | 0(D) | View → |
| May 8, 2026 | May 8 9:26 PM | Robert Luther HuffinesDirector | Grant/Award | 210 | — | 404(D) | View → |
| May 8, 2026 | May 8 9:25 PM | Carrie L ByingtonDirector | Grant/Award | 105 | — | 3,699(D) | View → |
| Feb 4, 2026 | Feb 5 5:24 PM | Robert Luther HuffinesDirector | Grant/Award | 100 | — | 100(D) | View → |
| Feb 4, 2026 | Feb 5 5:21 PM | Carrie L ByingtonDirector | Grant/Award | 30 | — | 1,714(D) | View → |
| Feb 4, 2026 | Feb 5 5:18 PM | Christopher Ian Montague JonesDirector | Grant/Award | 272 | — | 11,649(D) | View → |
| Jan 15, 2026 | Jan 16 8:43 PM | Michael David GarrisonEVP & Pres Med.Essntl&BioPharm | Option Exercise | 3,054 | $167.91 | 0(D) | View → |